Surrogate endpoints poor proxy for survival in cancer drug approval process

Surrogate endpoints used to support the majority of new cancer drugs approved in the US often lack formal study, according to the authors of a new report. This analysis questions whether the US Food and Drug Administration is adhering to standards that demand that surrogates be ‚reasonably likely to predict‘ or ‚established‘ to be used to grant approvals. (Mehr in: Cancer News — ScienceDaily)